AbbVie PE Ratio 2010-2018 | ABBV

Current and historical p/e ratio for AbbVie (ABBV) from 2010 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AbbVie PE ratio as of April 22, 2019 is 9.88.
AbbVie PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-04-22 78.15 21.83
2018-12-31 91.04 $3.58 25.43
2018-09-30 92.42 $4.84 19.10
2018-06-30 89.64 $4.04 22.19
2018-03-31 90.63 $3.97 22.83
2017-12-31 91.94 $3.29 27.95
2017-09-30 83.89 $4.11 20.41
2017-06-30 67.85 $4.07 16.67
2017-03-31 60.37 $3.86 15.64
2016-12-31 57.42 $3.63 15.82
2016-09-30 57.30 $3.70 15.49
2016-06-30 55.75 $3.47 16.07
2016-03-31 50.95 $3.32 15.35
2015-12-31 52.26 $3.12 16.75
2015-09-30 47.54 $1.69 28.13
2015-06-30 58.28 $1.26 46.26
2015-03-31 50.36 $1.11 45.37
2014-12-31 55.87 $1.09 51.25
2014-09-30 48.94 $2.30 21.28
2014-06-30 47.45 $2.59 18.32
2014-03-31 42.83 $2.57 16.67
2013-12-31 43.65 $2.56 17.05
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $115.278B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $369.784B 16.77
Pfizer (PFE) United States $232.043B 12.99
Merck (MRK) United States $198.062B 16.93
Novartis AG (NVS) Switzerland $174.174B 14.81
Eli Lilly (LLY) United States $119.606B 20.77
Novo Nordisk (NVO) Denmark $117.534B 19.01
Sanofi (SNY) France $103.709B 12.80
GlaxoSmithKline (GSK) United Kingdom $98.430B 12.93
AstraZeneca (AZN) United Kingdom $98.150B 11.20
Bristol-Myers Squibb (BMY) United States $73.920B 11.37